Insmed (INSM) Short term Debt (2012 - 2024)

Insmed (INSM) posted quarterly Short term Debt of $224.4 million for Q2 2024, little changed quarter-over-quarter from $224.2 million in Q1 2024.

Analysis

Insmed (INSM) Short term Debt (2012 - 2024) Analysis & Trends

Insmed's Short term Debt history runs 6 years deep, the most recent figure standing at $224.4 million for Q2 2024.

In Q2 2024, Short term Debt changed N/A year-over-year to $224.4 million; the TTM figure through Jun 2024 stood at $224.4 million (changed N/A YoY), while the FY2015 annual figure was $3.1 million, changed N/A from the prior year.
Short term Debt for Q2 2024 stood at $224.4 million, roughly flat from $224.2 million in the prior quarter.
The five-year high for Short term Debt was $224.4 million in Q2 2024, with the low at $224.2 million in Q1 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.78 Bn	130.92 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.50 Bn	77.51 Bn	3.93 Bn
3	Argenx Se	63.51 Bn	58.32 Bn	1.37 Bn
4	Moderna	58.06 Bn	52.92 Bn	52.00 Mn
5	Revolution Medicines	44.04 Bn	44.04 Bn	-
6	BeOne Medicines	40.04 Bn	34.94 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.45 Bn	32.14 Bn	992.69 Mn
8	Royalty Pharma	28.41 Bn	27.57 Bn	-
9	Insmed	27.42 Bn	26.26 Bn	358.27 Mn
10	Incyte	25.61 Bn	21.07 Bn	1.57 Bn

Historic Data

Download Data